Freenome, Inc.
FRNM
Positions held
Your positionsFRNM isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Freenome operates in the rapidly growing diagnostics and research sector, focusing on early cancer detection, which is becoming increasingly vital as healthcare systems prioritize preventive care.
- Freenome's market cap is approximately $1.76 billion, indicating strong investor interest and potential for growth.
- The company's revenue growth rate stands at 106.5%, showcasing its ability to expand and capture market share.
- The company has a negative forward P/E ratio of -6.82, indicating potential challenges in profitability and investor confidence.
- Freenome's operating margin is currently -28.68%, reflecting ongoing operational losses that could hinder future performance.
- The stock's price-to-book ratio is -0.31, suggesting that the company may be undervalued or facing significant financial difficulties.
Fundamentals
| Market cap | $1.70B | Enterprise value | $3.27B | Trailing P/E | — | Forward P/E | -6.59 |
| PEG | — | Price / book | -0.30 | Beta | 0.45 | Dividend yield | 0.00% |
| Revenue growth | 106.5% | Earnings growth | — | Gross margin | 0.0% | Operating margin | -28.7% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | 1.05 | Free cash flow | — | Analyst recommendation | none | Mean target | $18.00 |
| 52w high | $17.50 | 52w low | $9.95 |
Quarterly
No data yet.
Yearly (6y)
| 2025 | 2024 | |
|---|---|---|
| Revenue | $30.4M | $2.9M |
| Op margin | -734.9% | -10130.9% |
| Net income | -$219M | -$274M |
| Gross margin | 93.6% | 11.0% |
| Gross profit | $28.5M | $0.3M |
| Operating income | -$223M | -$292M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-08-12 · FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test
2026-08-11 · Freenome (FRNM) Climbed, But What Is Driving Attention Now?
2026-07-31 · Guardant Health, Thursday's Stock Of The Day, Spikes After Hiking 2026 Outlook
2026-07-27 · FDA Approves Freenome’s SimpleScreen™ CRC Blood-Based Screening Test; Abbott to Commercialize in the U.S.
2026-07-20 · Freenome Debuts as a Publicly Traded Company Focused on Blood-Based Early Cancer Detection
Price (daily)
Full chart · RSI · MACD · patterns